Benhuai Xie

835 total citations
17 papers, 663 citations indexed

About

Benhuai Xie is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Benhuai Xie has authored 17 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Benhuai Xie's work include CAR-T cell therapy research (11 papers), Biosimilars and Bioanalytical Methods (7 papers) and Gene expression and cancer classification (4 papers). Benhuai Xie is often cited by papers focused on CAR-T cell therapy research (11 papers), Biosimilars and Bioanalytical Methods (7 papers) and Gene expression and cancer classification (4 papers). Benhuai Xie collaborates with scholars based in United States. Benhuai Xie's co-authors include Wei Pan, Xiaotong Shen, Charles Burant, Charlie Cao, Majid Vakilynejad, Prabhakar Viswanathan, John Marcinak, Eckhard Leifke, Tanya Siddiqi and Jon Arnason and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Benhuai Xie

17 papers receiving 642 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benhuai Xie United States 12 319 299 146 126 120 17 663
Rachel Brandt United States 12 328 1.0× 452 1.5× 245 1.7× 163 1.3× 131 1.1× 27 1.1k
Harikrishna Paik India 10 144 0.5× 451 1.5× 17 0.1× 42 0.3× 46 0.4× 37 788
Chenghua Yang China 10 73 0.2× 313 1.0× 179 1.2× 387 3.1× 249 2.1× 24 774
Tamás Micsík Hungary 14 90 0.3× 236 0.8× 20 0.1× 109 0.9× 31 0.3× 50 625
Xiaohai Wang China 17 105 0.3× 388 1.3× 30 0.2× 88 0.7× 33 0.3× 38 775
Nicholas J. Wang United States 15 192 0.6× 408 1.4× 13 0.1× 55 0.4× 265 2.2× 21 984
Haining Zhou China 14 223 0.7× 300 1.0× 16 0.1× 167 1.3× 31 0.3× 52 767
Jian Shen China 19 181 0.6× 815 2.7× 23 0.2× 197 1.6× 19 0.2× 50 1.4k
Yejun Qin China 17 114 0.4× 371 1.2× 29 0.2× 97 0.8× 24 0.2× 39 706
Jinlu Liu China 14 74 0.2× 175 0.6× 33 0.2× 106 0.8× 26 0.2× 32 552

Countries citing papers authored by Benhuai Xie

Since Specialization
Citations

This map shows the geographic impact of Benhuai Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benhuai Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benhuai Xie more than expected).

Fields of papers citing papers by Benhuai Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benhuai Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benhuai Xie. The network helps show where Benhuai Xie may publish in the future.

Co-authorship network of co-authors of Benhuai Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Benhuai Xie. A scholar is included among the top collaborators of Benhuai Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benhuai Xie. Benhuai Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Abramson, Jeremy S., Maria Lia Palomba, Jon Arnason, et al.. (2019). Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.. Journal of Clinical Oncology. 37(15_suppl). 7515–7515. 13 indexed citations
2.
Wang, Michael, Leo I. Gordon, Maria Lia Palomba, et al.. (2019). Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.. Journal of Clinical Oncology. 37(15_suppl). 7516–7516. 12 indexed citations
3.
Abramson, Jeremy S., Tanya Siddiqi, M. Lia Palomba, et al.. (2018). High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product with Potential for Outpatient Administration. Biology of Blood and Marrow Transplantation. 24(3). S25–S25. 11 indexed citations
4.
Abramson, Jeremy S., Leo I. Gordon, Maria Lia Palomba, et al.. (2018). Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.. Journal of Clinical Oncology. 36(15_suppl). 7505–7505. 131 indexed citations
5.
Siddiqi, Tanya, Jeremy S. Abramson, Maria Lia Palomba, et al.. (2018). Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).. Journal of Clinical Oncology. 36(5_suppl). 122–122. 8 indexed citations
6.
Abramson, Jeremy S., Tanya Siddiqi, Maria Lia Palomba, et al.. (2018). High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.. Journal of Clinical Oncology. 36(5_suppl). 120–120. 24 indexed citations
7.
8.
Swanson, Christina, Trevor Do, Claire L. Sutherland, et al.. (2017). Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration. Blood. 130. 194–194. 6 indexed citations
9.
10.
Heipel, Mark, Jeffrey A. Smith, Mandana Karimi, et al.. (2017). Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017. Blood. 130. 2835–2835. 1 indexed citations
11.
Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2017). CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).. Journal of Clinical Oncology. 35(15_suppl). 7513–7513. 20 indexed citations
12.
13.
Burant, Charles, Prabhakar Viswanathan, John Marcinak, et al.. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 379(9824). 1403–1411. 212 indexed citations
14.
Pan, Wei, Benhuai Xie, & Xiaotong Shen. (2009). Incorporating Predictor Network in Penalized Regression with Application to Microarray Data. Biometrics. 66(2). 474–484. 80 indexed citations
15.
Xie, Benhuai, Wei Pan, & Xiaotong Shen. (2009). Penalized mixtures of factor analyzers with application to clustering high-dimensional microarray data. Bioinformatics. 26(4). 501–508. 20 indexed citations
16.
Xie, Benhuai, Wei Pan, & Xiaotong Shen. (2007). Variable Selection in Penalized Model‐Based Clustering Via Regularization on Grouped Parameters. Biometrics. 64(3). 921–930. 30 indexed citations
17.
Li, Na, Baolin Wu, Peng Wei, et al.. (2007). Functional group-based linkage analysis of gene expression trait loci. BMC Proceedings. 1(S1). S117–S117. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Brandt Breakdown of academic impact, for papers by Harikrishna Paik Breakdown of academic impact, for papers by Chenghua Yang Breakdown of academic impact, for papers by Tamás Micsík Breakdown of academic impact, for papers by Xiaohai Wang Breakdown of academic impact, for papers by Nicholas J. Wang Breakdown of academic impact, for papers by Haining Zhou Breakdown of academic impact, for papers by Jian Shen Breakdown of academic impact, for papers by Yejun Qin Breakdown of academic impact, for papers by Jinlu Liu
Rankless by CCL
2026